FindTrial
Sign In

Use of marker PKM1 and PKM2 in predicting hidden malignancy, in cases of a precancerous condition called atypical endometrial hyperplasia

Use of pyruvate kinase M1 and M2 biomarker in predicting coexistent carcinoma endometrium, in cases of atypical endometrial hyperplasia, to facilitate choice of fertility sparing surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/01/030352
Enrollment
60
Registered
2021-01-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N938- Other specified abnormal uterine and vaginal bleeding

Interventions

None listed

Sponsors

Research committee
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cases 1. Histopathological diagnosis of atypical endometrial hyperplasia on endometrial biopsy specimen 2. Patient willing to undergo hysterectomy 3. Final diagnosis of endometrial carcinoma on hysterectomy specimen. 4. Willing to participate in the study Controls 1. Histopathological diagnosis of atypical endometrial hyperplasia on endometrial biopsy specimen 2. Patient willing to undergo hysterectomy 3. Final diagnosis of AEH on hysterectomy specimen. 4. Willing to participate in the study

Exclusion criteria

Exclusion criteria: Cases 1. Patients not willing for hysterectomy 2. Received medical treatment before surgery Controls 1. Patients not willing for hysterectomy 2. Patients received medical treatment before surgery

Design outcomes

Primary

MeasureTime frame
1. Immunohistochemical staining pattern with PKM1 and PKM2 in endometrial biopsy slides with final diagnosis of endometrial carcinoma 2. Immunohistochemical staining pattern with PKM1 and PKM2 in endometrial biopsy slides with final diagnosis of atypical endometrial hyperplasia Timepoint: prospectively for 1.5 year after approval of project—

Secondary

MeasureTime frame
i. 1. Immunohistochemical staining pattern of EB slides with final diagnosis of EC of various grades 2. IHC staining pattern of PKM1 and PKM2 in EH without atypia 3. IHC staining pattern of PKM1 and PKM2 in normal endometrium Timepoint: prospectively for 1.5 year after approval of project—

Countries

India

Contacts

Public ContactRicha Vatsa

AIIMS, New Delhi

dr.richavatsa@gmail.com9810248161

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026